Skip to main content
SpringerLink
Log in

Vascular Sarcomas

  • Chapter
  • First Online:
Book cover Management of Soft Tissue Sarcoma

  • 1501 Accesses

Abstract

Vascular tumors run the gamut from benign hemangiomas to low-grade epithelioid hemangioendotheliomas, to highly aggressive angiosarcomas. We refrain in this section in discerning vascular sarcomas from similar tumors arising from lymphatics (lymphangiosarcomas) as there have not been good markers to definitively separate the two forms of tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Cancer. 1982;50:970–81.

    Article  CAS  PubMed  Google Scholar 

  2. Mentzel T, Beham A, Calonje E, et al. Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases [Article]. Am J Surg Pathol. 1997;21:363–74.

    Article  CAS  PubMed  Google Scholar 

  3. Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer. 2011;50:644–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Tanas MR, Sboner A, Oliveira AM, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med. 2011;3:98ra82.

    Google Scholar 

  5. Antonescu CR, Le Loarer F, Mosquera JM, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52:775–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Chevreau C, Le Cesne A, Ray-Coquard I, et al. Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Cancer. 2013;119:2639–44.

    Article  CAS  PubMed  Google Scholar 

  7. Deyrup AT, Tighiouart M, Montag AG, et al. Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. Am J Surg Pathol. 2008;32:924–7.

    Article  PubMed  Google Scholar 

  8. Walther C, Tayebwa J, Lilljebjorn H, et al. A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma. J Pathol. 2014;232:534–40.

    Article  CAS  PubMed  Google Scholar 

  9. Antonescu CR, Chen HW, Zhang L, et al. ZFP36-FOSB fusion defines a subset of epithelioid hemangioma with atypical features. Genes Chromosomes Cancer. 2014;53:951–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11:241–7.

    Article  PubMed  Google Scholar 

  11. Meis-Kindblom JM, Kindblom LG. Angiosarcoma of soft tissue: a study of 80 cases. Am J Surg Pathol. 1998;22:683–97.

    Article  CAS  PubMed  Google Scholar 

  12. Fletcher CD, Beham A, Bekir S, et al. Epithelioid angiosarcoma of deep soft tissue: a distinctive tumor readily mistaken for an epithelial neoplasm. Am J Surg Pathol. 1991;15:915–24.

    Article  CAS  PubMed  Google Scholar 

  13. Mayer F, Aebert H, Rudert M, et al. Primary malignant sarcomas of the heart and great vessels in adult patients—a single-center experience. Oncologist. 2007;12:1134–42.

    Article  PubMed  Google Scholar 

  14. McGowan TS, Cummings BJ, O’Sullivan B, et al. An analysis of 78 breast sarcoma patients without distant metastases at presentation. Int J Radiat Oncol Biol Phys. 2000;46:383–90.

    Article  CAS  PubMed  Google Scholar 

  15. Espat NJ, Lewis JJ, Woodruff JM, et al. Confirmed angiosarcoma: prognostic factors and outcome in 50 prospectively followed patients. Sarcoma. 2000;4:173–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer. 1948;1:64–81.

    Article  CAS  PubMed  Google Scholar 

  17. Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009;69:7175–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Behjati S, Tarpey PS, Sheldon H, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet. 2014;46:376–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Murali R, Chandramohan R, Moller I, et al. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget. 2015;6:36041–52.

    PubMed  PubMed Central  Google Scholar 

  20. Casper ES, Waltzman RJ, Schwartz GK, et al. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest. 1998;16:442–6.

    Article  CAS  PubMed  Google Scholar 

  21. Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005;104:361–6.

    Article  CAS  PubMed  Google Scholar 

  22. Young RJ, Natukunda A, Litiere S, et al. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. Eur J Cancer. 2014;50:3178–86.

    Article  CAS  PubMed  Google Scholar 

  23. Maki RG, D’Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ray-Coquard I, Italiano A, Bompas E, et al. Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012;17:260–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ray-Coquard IL, Domont J, Tresch-Bruneel E, et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial. J Clin Oncol. 2015;33:2797–802.

    Article  CAS  PubMed  Google Scholar 

  26. Dabska M. Malignant endovascular papillary angioendothelioma of the skin in childhood. Clinicopathologic study of 6 cases. Cancer. 1969;24:503–10.

    Article  CAS  PubMed  Google Scholar 

  27. Kaposi M. Idiopathisches multiples pigmentsarkom der Haut. Arch Dermatol Syph. 1872;4:265–73.

    Article  Google Scholar 

  28. Shiels RA. A history of Kaposi’s sarcoma. J R Soc Med. 1986;79:532–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Bodsworth NJ, Bloch M, Bower M, et al. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi’s sarcoma. Am J Clin Dermatol. 2001;2:77–87.

    Article  CAS  PubMed  Google Scholar 

  30. Ramirez-Amador V, Esquivel-Pedraza L, Lozada-Nur F, et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi’s sarcoma. A double blind, randomized clinical trial. Oral Oncol. 2002;38:460–7.

    Article  CAS  PubMed  Google Scholar 

  31. Jham BC, Montaner S. The Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor: lessons on dysregulated angiogenesis from a viral oncogene. J Cell Biochem. 2010;110:1–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Hahn AS, Kaufmann JK, Wies E, et al. The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi’s sarcoma-associated herpesvirus. Nat Med. 2012;18:961–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. He M, Zhang W, Bakken T, et al. Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2. Cancer Res. 2012;72:3582–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Roy D, Sin SH, Lucas A, et al. mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res. 2013;73:2235–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16:2445–51.

    CAS  PubMed  Google Scholar 

  36. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998;16:683–91.

    CAS  PubMed  Google Scholar 

  37. Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma. Cancer. 2010;116:3969–77.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Uthayakumar S, Bower M, Money-Kyrle J, et al. Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi’s sarcoma. AIDS. 1996;10:515–9.

    Article  CAS  PubMed  Google Scholar 

  39. Lim ST, Tupule A, Espina BM, et al. Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer. 2005;103:417–21.

    Article  CAS  PubMed  Google Scholar 

  40. Krown SE, Lee JY, Lin L, et al. Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial. J Acquir Immune Defic Syndr. 2006;41:149–53.

    Article  CAS  PubMed  Google Scholar 

  41. Little RF, Pluda JM, Wyvill KM, et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood. 2006;107:4650–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Evans SR, Krown SE, Testa MA, et al. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi’s sarcoma: an AIDS clinical trials group clinical study. J Clin Oncol. 2002;20:3236–41.

    Article  CAS  PubMed  Google Scholar 

  43. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317–23.

    Article  CAS  PubMed  Google Scholar 

  44. Marfo K, Greenstein S. Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplant Proc. 2009;41:3796–9.

    Article  CAS  PubMed  Google Scholar 

  45. Steff M, Joly V, Di Lucca J, et al. Clinical activity of lenalidomide in visceral human immunodeficiency virus–related Kaposi sarcoma. JAMA Derm. 2013;149:1319–22.

    Article  Google Scholar 

  46. Uldrick TS, Wyvill KM, Kumar P, et al. Phase II study of bevacizumab in patients with HIV-associated Kaposi’s sarcoma receiving antiretroviral therapy. J Clin Oncol. 2012;30:1476–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. International Center Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Murray F. Brennan MD

  2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Cristina R. Antonescu MD

  3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Kaled M. Alektiar MD

  4. Monter Cancer Center, Hofstra Northwell School of Medicine and Cold Spring Harbor Laboratory, Lake Success, NY, USA

    Robert G. Maki MD, PhD

Authors
  1. Murray F. Brennan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina R. Antonescu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kaled M. Alektiar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert G. Maki MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Brennan, M.F., Antonescu, C.R., Alektiar, K.M., Maki, R.G. (2016). Vascular Sarcomas. In: Management of Soft Tissue Sarcoma. Springer, Cham. https://doi.org/10.1007/978-3-319-41906-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-41906-0_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-41904-6

  • Online ISBN: 978-3-319-41906-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation